Back to Search Start Over

Eteplirsen Use in a Boy with Duchenne Muscular Dystrophy and Sickle Cell Anemia

Authors :
Gregory M. Aiello
Michael Stephen Cartwright
Source :
Case Reports in Neurology. 14:396-399
Publication Year :
2022
Publisher :
S. Karger AG, 2022.

Abstract

Eteplirsen is an antisense oligonucleotide used in the treatment of Duchenne muscular dystrophy (DMD). The safety of eteplirsen use in individuals with rare comorbid conditions is not known. We present the case of a 4-year-old boy with a DMD exon deletion amenable to treatment with eteplirsen and comorbid sickle cell anemia. He has received eteplirsen treatment for 3 years with no clear adverse effects, including no increase in sickle cell crises.

Subjects

Subjects :
Neurology (clinical)

Details

ISSN :
1662680X
Volume :
14
Database :
OpenAIRE
Journal :
Case Reports in Neurology
Accession number :
edsair.doi...........2b0ec44b5ba0c43a761dd6dc247bd896
Full Text :
https://doi.org/10.1159/000527358